As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn’t save who have most affected his path.

The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

Discussing prognosis and a treatment plan has been getting particularly complicated with acute myelogenous leukemia with the development and use of molecular markers that confer prognostic and therapeutic information.

The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.